News and Comments

JUNO Surged After the FDA Removed the Clinical Hold of the ROCKET Trial. See Also: Why SAGE Surged

  Wednesday, July 13, 2016

JUNO   More...

Biotech Firms with Guaranteed Growth Potential

  Thursday, July 07, 2016

Good news is not always great news that makes a difference. In the drug industry, clinical trial results that demonstrate a drug has fulfilled the requirements of the trials, including the primary and secondary endpoints does not always guarantee that the drug will be successful if and when it hits the market. Experience and follow up on certain firms enables us to see the real light at the end of the tunnel, not just celebrate reaching the end of it without knowing what to expect outside. This makes a big difference.  More...

The Royal Divorce. Gilead Rallied Not Plummeted

  Wednesday, June 29, 2016

The Royal Divorce More...

The Biotech Sector Evolution in the News

  Wednesday, June 22, 2016

Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study of the Closed Triple combination of fluticasone furoate, umeclidinium, and vilanterol) for patients with chronic obstructive pulmonary disease (COPD).  More...

SPARK Therapeutics History Foretells Its Triumph in Gene Therapy

  Thursday, June 16, 2016

SPARK More...

Good News for Agenus and for Global Blood Therapeutics

  Friday, June 10, 2016

Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration with Merck, which is known as MSD outside the United States and Canada.   More...

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

  Thursday, June 02, 2016

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) means more than pressuring the FDA to approve Sarepta’s DMD product eteplirsen.  More...

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

  Friday, May 27, 2016

 More...

Great News for Innoviva and COPD Patients

  Wednesday, May 25, 2016

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) Demonsterates Superiority Over Usual Care. More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...


Recent Postings


Archive


Tags

Biocryst (BCRX) Intercept (ICPT) Agenus (AGEN) AGOS (ARGS) Telaprevir NANTKWEST (NK) Prosensa (RNA) Human Longevity (HLI) C4 Therapeutics Adaptimmune (ADAP) OSI (OSIP) Ionis (IONS) Anadys (ANDS) JUNO (JUNO) ARGOS (ARGS) BIOMARIN (BMRN) Biogen Idec (BIIB) Rapamune AstraZeneca (AZN) NEKTAR (NKTR)) Incyte (INCY) AERIE PHARMACEUTICALS Merck (MRK) Zerenex Ziofpharm (ZIOP) RenenxBio (RGNX) Idenix (IDIX) Genentech Velcade (bortezomib) REGULUS (RGLS) Vertex (VRTX) Benlysta (belimumab) Agenus (AGEN Regeneron (REGN) VANDA (VNDA) Onyx (ONXX) Amgen (AMGN) galapagos (GLPG) Ridaforolimus Sangamo (SGMO) Sequenom (SQNM) Abbott Laboratories (ABT) GlaxoSmithKline (GSK) SUNESIS PHARMACEUTICALS (SNSS) Jazz Pharmaceuticals (JAZZ) Seattle Genetics (SGEN) Editas (EDIT) Endometrial Cancer Prolor Biotech (PBTH) Dynavax (DVAX) Auspex (ASPX) ISIS (ISIS) ARCA (ABIO) Vitae Pharmaceuticals (VTAE) Mirati Therapeutics (MRTX) Aimmune Therapeutics (AIMT) ZALTRAP™ Tysabri ABBVIE (ABBV) Inovio (INO) Herceptin Roche (RHHBY) Theravance (THRX) Gilead (GILD) ImmunoGen (IMGN) Intrexon (XON) Theravance Bio Pharma (TBPH) Sanofi (SNA) Cytokinetics (CYTK) Array Pharmaceuticals (ARRY) Sarepta (SRPT) TOKAI (TKAOI) Human Genome Sciences (HGSI) IDERA (IDRA) Galena (GALE) KITE (KITE) Illumina (ILMN) ACADIA (ACAD) KERYX (KERX) PTC Therapeutics (PTCT) Sanofi (SNY) SERES THERAPEUTICS (MCRB) Bristol-Myers Squibb (BMY) Dendreon (DNDN) Sanofi-Aventis (SAN) Global Cell Therapeutics (GBT) SYNTA (SNTA) Revlimid (lenolidamide) Anacor (ANAC) Alder Biopharmaceuticals (ALDR) Ariad (ARIA) ADVENTRIX (ANX) CRISPR Therapeutics (CRSP) Exelixis (EXEL) NOVOCURE (NVCR) Valeant Pharmaceuticals International (VRX) Bellicum (BLCM) Xoma (XOMA) Pluristem (PSTI) HALOZYME (HALO) Roche (ROCHE) Alnylam (ALNY) Multiple Myeloma CompuGen (CGEN) Spike Therapeutics (ONCE) Trastuzumab-DM1 Micromet (MITI) INNOVIVA (INVA) GUARDIAN HEALTH Intermune (ITMN) MODERNA Advaxis (ADXS) Elan (ELN)